A new mechanism of acquired clinical resistance in two patients with acute myeloid leukaemia driven by mutant IDH2 is described, in which a second-site mutation on the wild-type allele induces therapeutic resistance to IDH2 inhibitors.
- Andrew M. Intlekofer
- Alan H. Shih
- Eytan M. Stein
